ArticleAmerican journal of translational research2026
Circulating tumor DNA mediates the effect of intrapleural cisplatin retention on non-small cell lung cancer malignant pleural effusion.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo analyze the therapeutic effects of different cisplatin retention times on malignant pleural effusion and to explore whether circulating tumor DNA (ctDNA) played a mediating role in this process.
methodsA total of 207 patients with non-small cell lung cancer (NSCLC) and pleural effusion were enrolled. According to the retention time after intrapleural injection of cisplatin, patients were divided into three groups: a 1 h retention group (n=68), a 6 h retention group (n=69), and a 24 h retention group (n=70). The short-term efficacy (disease control rate, objective response rate) and long-term efficacy (progression-free survival, overall survival (OS)) were compared among the three groups, and the role of ctDNA was explored through mediation effect analysis.
resultsThe disease control rate in the 24 h retention group was 92.9%, significantly higher than that in the 6 h group (92.7%) and the 1 h group (80.9%) (
conclusions24 h intrapleural cisplatin retention significantly improves the short-term and long-term treatment outcomes in NSCLC patients with pleural effusion. Changes in ctDNA concentration play a key mediating role in this efficacy improvement, suggesting that ctDNA could serve as a novel potential biomarker for guiding personalized treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.